867 related articles for article (PubMed ID: 30825612)
41. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma.
Lu KH; Wu W; Dave B; Slomovitz BM; Burke TW; Munsell MF; Broaddus RR; Walker CL
Clin Cancer Res; 2008 May; 14(9):2543-50. PubMed ID: 18451215
[TBL] [Abstract][Full Text] [Related]
42. Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer.
Shen X; Zhao Y; Liu G; Zhou HL; Fan J; Zhang L; Li YL; Wang Y; Liang J; Xu ZX
Life Sci; 2020 Sep; 256():117923. PubMed ID: 32522567
[TBL] [Abstract][Full Text] [Related]
43. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
[TBL] [Abstract][Full Text] [Related]
44. Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth.
Smith MC; Mader MM; Cook JA; Iversen P; Ajamie R; Perkins E; Bloem L; Yip YY; Barda DA; Waid PP; Zeckner DJ; Young DA; Sanchez-Felix M; Donoho GP; Wacheck V
Mol Cancer Ther; 2016 Oct; 15(10):2344-2356. PubMed ID: 27439478
[TBL] [Abstract][Full Text] [Related]
45. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma.
Liu T; Sun Q; Li Q; Yang H; Zhang Y; Wang R; Lin X; Xiao D; Yuan Y; Chen L; Wang W
Mol Cancer Ther; 2015 Feb; 14(2):429-39. PubMed ID: 25504751
[TBL] [Abstract][Full Text] [Related]
46. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC).
Tan AC
Thorac Cancer; 2020 Mar; 11(3):511-518. PubMed ID: 31989769
[TBL] [Abstract][Full Text] [Related]
47. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.
Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA
Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781
[TBL] [Abstract][Full Text] [Related]
48. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.
Acquaviva J; Smith DL; Sang J; Friedland JC; He S; Sequeira M; Zhang C; Wada Y; Proia DA
Mol Cancer Ther; 2012 Dec; 11(12):2633-43. PubMed ID: 23012248
[TBL] [Abstract][Full Text] [Related]
49. Targeting epidermal growth factor receptor-associated signaling pathways in non-small cell lung cancer cells: implication in radiation response.
Choi EJ; Ryu YK; Kim SY; Wu HG; Kim JS; Kim IH; Kim IA
Mol Cancer Res; 2010 Jul; 8(7):1027-36. PubMed ID: 20587532
[TBL] [Abstract][Full Text] [Related]
50. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.
Nagata Y; Takahashi A; Ohnishi K; Ota I; Ohnishi T; Tojo T; Taniguchi S
Int J Oncol; 2010 Oct; 37(4):1001-10. PubMed ID: 20811722
[TBL] [Abstract][Full Text] [Related]
51. Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer.
Beale G; Haagensen EJ; Thomas HD; Wang LZ; Revill CH; Payne SL; Golding BT; Hardcastle IR; Newell DR; Griffin RJ; Cano C
Br J Cancer; 2016 Sep; 115(6):682-90. PubMed ID: 27529512
[TBL] [Abstract][Full Text] [Related]
52. A novel PI3K/mTOR dual inhibitor XH002 exhibited robust antitumor activity in NSCLC.
Lv Y; Du T; Ji M; Wang C; Lin S; Xue N; Jin J; Xu H; Chen X
J Drug Target; 2019 Apr; 27(4):451-459. PubMed ID: 30381967
[TBL] [Abstract][Full Text] [Related]
53. Negative regulation of mTOR activity by LKB1-AMPK signaling in non-small cell lung cancer cells.
Dong LX; Sun LL; Zhang X; Pan L; Lian LJ; Chen Z; Zhong DS
Acta Pharmacol Sin; 2013 Feb; 34(2):314-8. PubMed ID: 23178462
[TBL] [Abstract][Full Text] [Related]
54. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
55. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
56. LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer.
Han D; Li SJ; Zhu YT; Liu L; Li MX
Asian Pac J Cancer Prev; 2013; 14(7):4033-9. PubMed ID: 23991948
[TBL] [Abstract][Full Text] [Related]
57. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
58. The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis.
Xiao Y; Yu Y; Jiang P; Li Y; Wang C; Zhang R
Cell Oncol (Dordr); 2020 Aug; 43(4):669-680. PubMed ID: 32382996
[TBL] [Abstract][Full Text] [Related]
59. Cardamonin inhibits the proliferation and metastasis of non-small-cell lung cancer cells by suppressing the PI3K/Akt/mTOR pathway.
Zhou X; Zhou R; Li Q; Jie X; Hong J; Zong Y; Dong X; Zhang S; Li Z; Wu G
Anticancer Drugs; 2019 Mar; 30(3):241-250. PubMed ID: 30640793
[TBL] [Abstract][Full Text] [Related]
60. BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma.
Miao X; Liu C; Jiang Y; Wang Y; Kong D; Wu Z; Wang X; Tian R; Yu X; Zhu X; Gong W
Cell Death Dis; 2021 Oct; 12(11):1020. PubMed ID: 34716294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
